Amicus Therapeutics

Amicus Therapeutics, Inc.
Company typePublic
Nasdaq: FOLD
Russell 2000 Component
IndustryBiotechnology
FoundedFebruary 4, 2002; 22 years ago (2002-02-04)[1]: 28 
Headquarters
Philadelphia, Pennsylvania
,
United States
Key people
Revenue
  • Increase $91,245,000 (2018)
  • Increase $36,930,000 (2017)
  • Increase ($328,777,000) (2018)
  • Decrease ($441,985,000) (2017)
  • Increase ($349,089,000) (2018)
  • Decrease ($449,121,000) (2017)
Total assets
  • Increase $789,951,000 (2018)
  • Decrease $627,024,000 (2017)
Total equity
  • Decrease $342,912,000 (2018)
  • Decrease $352,850,000 (2017)
Number of employees
508 (31 Dec 2018)[1]: 28 
Websitewww.amicusrx.com
Footnotes / references
[1][2]

Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, PA.[3] The company went public in 2007 under the NASDAQ trading symbol FOLD.[4] This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX[5][6] Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.[7]

  1. ^ a b c "Form 10-K: Amicus Therapeutics, Inc". EDGAR. USSEC. 2018. p. 61. Retrieved 2024-03-04.
  2. ^ "Amicus Leader, BIO Board Member John Crowley Named Trade Group's New CEO". MedCity News. Dec 5, 2023. Retrieved 2024-03-04.
  3. ^ "Amicus Corporate Headquarters".
  4. ^ "Amicus Therapeutics IPO raises $75 mln, in range". Reuters. 30 May 2007.
  5. ^ Gelsi, Steve (17 May 2006). "Amicus Therapeutics files $86M IPO". MarketWatch.
  6. ^ Moyer, Liz (16 Aug 2006). "IPOs Head For The Exits". Forbes. There have been five withdrawn IPOs so far this month, including ... Amicus Therapeutics.
  7. ^ Rubin, Evelyn (18 May 2006). "Amicus IPO: A Very Risky Prospect (AMTX)". Seeking Alpha.